KLRS

1.3202.22%
AO

Andrew Oxtoby

President, CEO & Director

Mr. Andrew Oxtoby serves as Director at Aravax Pty Ltd since April 2026. He serves as President and Chief Executive Officer at Kalaris Therapeutics, Inc. from March 4, 2024. He is Director at Kalaris Therapeutics, Inc. since March 2024. He served as Chief Commercial Officer at Chinook Therapeutics, Inc. since February 2023 until August 11, 2023. He had been President and Chief Executive Officer at Aimmune Therapeutics, Inc. since October 13, 2020 and served as its Chief Commercial Officer since January 22, 2019 until October 13, 2020. Mr. Oxtoby serves as Director at Aimmune Therapeutics, Inc. since October 13, 2020. Mr. Oxtoby joins Aimmune from Eli Lilly and Company, where he most recently had responsibility for Lilly’s U.S. insulin business as Vice President of U.S. Diabetes Connected Care and Insulins, an innovative, patient-focused business unit, after having served as Vice President of U.S. Diabetes Sales. In his more than 16 years with Lilly, Mr. Oxtoby also spent five years in oncology, including as Vice President of the International Oncology business; served as General Manager of Lilly’s Netherlands operation; and held positions of increasing responsibility in marketing and sales. Mr. Oxtoby began his career at Procter & Gamble, where he spent four years in the engineering and manufacturing organizations. He currently serves on the board of Damien Center, a non-profit organization providing support and services to people living with HIV in central Indiana. He has vast nd biotechnology industry, including extensive global experience involving numerous product launches across a wide array of therapeutic areas. Mr. Oxtoby holds an M.B.A. from Harvard Business School and a B.S. in mechanical engineering from Purdue University.

Positions